CD19-CAR-T2 Cells
B Cell Leukemia
Nanfang Hospital, Southern Medical UniversityPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the B Cell Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Autologous 3Rd Generation Cd19-Targeting Car T Cells Uppsala University | Phase 1/2 | CCC |
Cart-19 And 20 Cells University of Pennsylvania | Phase 1/2 | CCC |
Tisagenlecleucel iCell Gene Therapeutics | Phase 1 | CCC |
Car-Itnk Cells Nanfang Hospital, Southern Medical University | Phase 1/2 | CCC |
Universal Dual Specificity Cd19 And Cd20 Or Cd22 Car-T Cells Chinese PLA General Hospital | Phase 1/2 | CCC |
View all 23 →
Same molecule, other indications
CD19-CAR-T2 Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →